We provide the best-in-class treatment solutions with humanity as the priority
VISEN Pharmaceuticals (Taiwan) has officially launched in Taiwan in 2021 as a foreign-funded enterprise. Putting patients in the first place to provide First-in-Class or Best-in-Class endocrinology medical products and treatment solutions, we are devoted to becoming an expert in the domain of endocrine-related treatment.
The scope of our treatments includes pediatric endocrine, adult endocrine, and rare endocrinological diseases. Top treatment solutions and drugs worldwide are imported to Taiwan, allowing patients with endocrine diseases in Taiwan to be synchronized with the world, to benefit from advanced and reliable treatment solutions, and enjoy a living quality with more dignity.
VISEN Pharmaceuticals was founded in 2018 by Ascendis Pharma A/S (Nasdaq:ASND) from Denmark, with Vivo Capital and Sofinnova Ventures from the United States. Ascendis Pharma A/S (Nasdaq:ASND) was founded in 2007, with its headquarters in Copenhagen, Denmark. It develops new-type treatment solutions utilizing the TransCon technological platform. Vivo Capital was developed in 1996, with its headquarters set in Palo Alto, California, United States. It is an investment company focusing on life science and the medical health domain. VISEN Pharmaceuticals (Taiwan) was founded in 2021, and the first product it will launch on the Taiwanese market is expected to be developed via the TransCon innovative technological platform, and be used for child endocrinological disease treatments, thereby allowing patients with endocrine diseases to experience a better treatment process with more reliable effects.
Gathers professionals and strengths from the global endocrine domain
Assists in innovations, enables breakthroughs, accelerates benefits for even more patients
Explores the unresolved demands of the endocrine domain
Offers innovative solutions with patients as the priority
Words from CEO
There are many challenges in the treatment of endocrine diseases. An innovative pharmaceutical company needs to go beyond treating disease, to treating patients. The evolution of treatment lies in achieving better treatment outcomes with more convenient and acceptable approaches. This is the original intention of VISEN, and also the commitment that VISEN will continue to live by in the future. We are dedicated to providing innovative therapies and compassionate, patient-centric care to help more endocrine patients to gain back their health and pursue the lives they desire.
Pony LU
CEO of VISEN Pharmaceutical
We consider it a social mission to provide innovative clinical solutions to meet the clinical needs that could not be satisfied for many years. We hope to build a professional, communicative, efficient, and innovative VISEN team with tenacity and humanistic care, allowing partners to work here happily with pride. VISEN Pharmaceuticals will actively participate in collaborative opportunities with the medical and academic field, the government, and patient organizations, gathering professional and capable people from the domestic and international endocrinological treatment domain to introduce even better treatment solutions for patients with endocrine diseases.
Popo LIN
VP of Taiwan Operation VISEN Pharmaceuticals (Taiwan)
Our Vision
Every endocrine patient can live life to the fullest with innovative therapies and compassionate care.
Our Mission
Achieve better treatment processes and outcomes for endocrine patients by combining global expertise and resources to focus on innovative endocrine therapies.
